Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir.

HIV-1 (human immunodeficiency virus type 1) protease (PR) and its mutants are important antiviral drug targets. The PR flap region is critical for binding substrates or inhibitors and catalytic activity. Hence, mutations of flap residues frequently contribute to reduced susceptibility to PR inhibitors in drug-resistant HIV. Structural and kinetic analyses were used to investigate the role of flap residues Gly48, Ile50, and Ile54 in the development of drug resistance. The crystal structures of flap mutants PR(I50V) (PR with I50V mutation), PR(I54V) (PR with I54V mutation), and PR(I54M) (PR with I54M mutation) complexed with saquinavir (SQV) as well as PR(G48V) (PR with G48V mutation), PR(I54V), and PR(I54M) complexed with darunavir (DRV) were determined at resolutions of 1.05-1.40 A. The PR mutants showed changes in flap conformation, interactions with adjacent residues, inhibitor binding, and the conformation of the 80s loop relative to the wild-type PR. The PR contacts with DRV were closer in PR(G48V)-DRV than in the wild-type PR-DRV, whereas they were longer in PR(I54M)-DRV. The relative inhibition of PR(I54V) and that of PR(I54M) were similar for SQV and DRV. PR(G48V) was about twofold less susceptible to SQV than to DRV, whereas the opposite was observed for PR(I50V). The observed inhibition was in agreement with the association of G48V and I50V with clinical resistance to SQV and DRV, respectively. This analysis of structural and kinetic effects of the mutants will assist in the development of more effective inhibitors for drug-resistant HIV.

[1]  J. Louis,et al.  Structural implications of drug‐resistant mutants of HIV‐1 protease: High‐resolution crystal structures of the mutant protease/substrate analogue complexes , 2001, Proteins.

[2]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[3]  Arun K. Ghosh,et al.  Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M. , 2006, Journal of medicinal chemistry.

[4]  C. Hutchison,et al.  Sequence requirements of the HIV-1 protease flap region determined by saturation mutagenesis and kinetic analysis of flap mutants. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[5]  R M Esnouf,et al.  Further additions to MolScript version 1.4, including reading and contouring of electron-density maps. , 1999, Acta crystallographica. Section D, Biological crystallography.

[6]  J. Louis,et al.  Flap opening and dimer-interface flexibility in the free and inhibitor-bound HIV protease, and their implications for function. , 1999, Structure.

[7]  M Karplus,et al.  Relation between sequence and structure of HIV-1 protease inhibitor complexes: a model system for the analysis of protein flexibility. , 2002, Journal of molecular biology.

[8]  Philippe Flandre,et al.  Factors Associated with the Selection of Mutations Conferring Resistance to Protease Inhibitors (PIs) in PI-Experienced Patients Displaying Treatment Failure on Darunavir , 2007, Antimicrobial Agents and Chemotherapy.

[9]  Peter Briggs,et al.  A graphical user interface to the CCP4 program suite. , 2003, Acta crystallographica. Section D, Biological crystallography.

[10]  Ladislau C. Kovari,et al.  Crystal Structures of a Multidrug-Resistant Human Immunodeficiency Virus Type 1 Protease Reveal an Expanded Active-Site Cavity , 2004, Journal of Virology.

[11]  C. Petropoulos,et al.  Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy. , 2000, The Journal of infectious diseases.

[12]  Irene T Weber,et al.  Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease. , 2007, Journal of medicinal chemistry.

[13]  R M Esnouf,et al.  An extensively modified version of MolScript that includes greatly enhanced coloring capabilities. , 1997, Journal of molecular graphics & modelling.

[14]  Irene T Weber,et al.  Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S. , 2005, Journal of molecular biology.

[15]  B. Dunn,et al.  The contribution of naturally occurring polymorphisms in altering the biochemical and structural characteristics of HIV-1 subtype C protease. , 2008, Biochemistry.

[16]  J. Louis,et al.  Structural and kinetic analysis of drug resistant mutants of HIV-1 protease. , 2000, European journal of biochemistry.

[17]  I. Weber,et al.  Comparison of inhibitor binding in HIV‐1 protease and in non‐viral aspartic proteases: the role of the flap , 1990, FEBS letters.

[18]  Irene T Weber,et al.  Mechanism of drug resistance revealed by the crystal structure of the unliganded HIV-1 protease with F53L mutation. , 2006, Journal of molecular biology.

[19]  Soo-Yon Rhee,et al.  HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance , 2007, AIDS.

[20]  Irene T Weber,et al.  Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 Å resolution crystal structures of HIV‐1 protease mutants with substrate analogs , 2005, The FEBS journal.

[21]  B. Torbett,et al.  Conformational flexibility in the flap domains of ligand-free HIV protease. , 2007, Acta crystallographica. Section D, Biological crystallography.

[22]  Dirk Jochmans,et al.  TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical Isolates , 2005, Antimicrobial Agents and Chemotherapy.

[23]  L Hong,et al.  Crystal structure of an in vivo HIV‐1 protease mutant in complex with saquinavir: Insights into the mechanisms of drug resistance , 2000, Protein science : a publication of the Protein Society.

[24]  G. Sheldrick,et al.  SHELXL: high-resolution refinement. , 1997, Methods in enzymology.

[25]  G. Marius Clore,et al.  Autoprocessing of HIV-1 protease is tightly coupled to protein folding , 1999, Nature Structural Biology.

[26]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .

[27]  Irene T Weber,et al.  Atomic resolution crystal structures of HIV‐1 protease and mutants V82A and I84V with saquinavir , 2007, Proteins.

[28]  T. Merigan,et al.  Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations. , 1999, AIDS.

[29]  A Wlodawer,et al.  Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 A resolution. , 1989, Science.

[30]  H. B. Schock,et al.  An alternate binding site for the P1-P3 group of a class of potent HIV-1 protease inhibitors as a result of concerted structural change in the 80s loop of the protease. , 2000, Acta crystallographica. Section D, Biological crystallography.

[31]  Irene T Weber,et al.  High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. , 2004, Journal of molecular biology.

[32]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[33]  Hiroaki Mitsuya,et al.  Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV. , 2007, Bioorganic & medicinal chemistry.

[34]  A. Wlodawer,et al.  Structural characterization of B and non-B subtypes of HIV-protease: insights into the natural susceptibility to drug resistance development. , 2007, Journal of molecular biology.

[35]  Robert W. Shafer,et al.  Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance , 2002, Clinical Microbiology Reviews.

[36]  D. Ho,et al.  Ordered accumulation of mutations in HIV protease confers resistance to ritonavir , 1996, Nature Medicine.

[37]  Irene T Weber,et al.  Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114. , 2006, Journal of molecular biology.

[38]  F. Buonaguro,et al.  Human Immunodeficiency Virus Type 1 Subtype Distribution in the Worldwide Epidemic: Pathogenetic and Therapeutic Implications , 2007, Journal of Virology.

[39]  Celia A. Schiffer,et al.  Mechanism of Substrate Recognition by Drug-Resistant Human Immunodeficiency Virus Type 1 Protease Variants Revealed by a Novel Structural Intermediate , 2006, Journal of Virology.

[40]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[41]  Irene T. Weber,et al.  Novel bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC114) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus In Vitro , 2003, Antimicrobial Agents and Chemotherapy.

[42]  Irene T Weber,et al.  Caught in the Act: the 1.5 A resolution crystal structures of the HIV-1 protease and the I54V mutant reveal a tetrahedral reaction intermediate. , 2007, Biochemistry.

[43]  Alberto Diaspro,et al.  Frontiers in Drug Design and Discovery , 2006 .

[44]  D. Faulds,et al.  Saquinavir , 1996, Drugs.

[45]  C. Schiffer,et al.  Role of Invariant Thr80 in Human Immunodeficiency Virus Type 1 Protease Structure, Function, and Viral Infectivity , 2006, Journal of Virology.